Impact of the visceral leishmaniasis elimination initiative on Leishmania donovani transmission in Nepal: a 10-year repeat survey.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
02 2020
Historique:
received: 03 09 2019
revised: 05 11 2019
accepted: 19 11 2019
entrez: 26 1 2020
pubmed: 26 1 2020
medline: 4 7 2020
Statut: ppublish

Résumé

Nepal launched a visceral leishmaniasis (also known as kala-azar) elimination initiative in 2005. We primarily aimed to assess whether transmission of Leishmania donovani had decreased since the launch of the initiative. We also assessed the validity of the direct agglutination test (DAT) as a marker of infection, in view of future surveillance systems. We did a repeat survey in a population aged 2 years and older for whom baseline serological data were available from 2006. Data were from three districts in the eastern region of Nepal. The primary outcome of interest was prevalent infection with L donovani as measured with DAT (cutoff value ≥1:3200). We compared age group-specific and cluster-specific seroprevalences in 2016 with those in 2006, using χ Between Oct 17, 2016, and Dec 26, 2016, we assessed 6609 individuals. DAT prevalence in children younger than 10 years was 4·1% (95% CI 3·2-5·4) in 2006 versus 0·5% (0·1-1·7) in 2016 (p<0·0001). Seroprevalence was lower in 2016 than in 2006 in all age groups and in all repeated clusters. The overall adjusted risk ratio of being seropositive was 0·44 (95% CI 0·37-0·52) for 2016 compared with 2006, and 0·04 (0·01-0·16) in children younger than 10 years. Our findings show that transmission of L donovani in Nepal has decreased significantly between 2006 and 2016, coinciding with the elimination programme. DAT seems useful for monitoring of L donovani transmission. The Directorate-General for Development Cooperation of Belgium.

Sections du résumé

BACKGROUND
Nepal launched a visceral leishmaniasis (also known as kala-azar) elimination initiative in 2005. We primarily aimed to assess whether transmission of Leishmania donovani had decreased since the launch of the initiative. We also assessed the validity of the direct agglutination test (DAT) as a marker of infection, in view of future surveillance systems.
METHODS
We did a repeat survey in a population aged 2 years and older for whom baseline serological data were available from 2006. Data were from three districts in the eastern region of Nepal. The primary outcome of interest was prevalent infection with L donovani as measured with DAT (cutoff value ≥1:3200). We compared age group-specific and cluster-specific seroprevalences in 2016 with those in 2006, using χ
FINDINGS
Between Oct 17, 2016, and Dec 26, 2016, we assessed 6609 individuals. DAT prevalence in children younger than 10 years was 4·1% (95% CI 3·2-5·4) in 2006 versus 0·5% (0·1-1·7) in 2016 (p<0·0001). Seroprevalence was lower in 2016 than in 2006 in all age groups and in all repeated clusters. The overall adjusted risk ratio of being seropositive was 0·44 (95% CI 0·37-0·52) for 2016 compared with 2006, and 0·04 (0·01-0·16) in children younger than 10 years.
INTERPRETATION
Our findings show that transmission of L donovani in Nepal has decreased significantly between 2006 and 2016, coinciding with the elimination programme. DAT seems useful for monitoring of L donovani transmission.
FUNDING
The Directorate-General for Development Cooperation of Belgium.

Identifiants

pubmed: 31981555
pii: S2214-109X(19)30536-4
doi: 10.1016/S2214-109X(19)30536-4
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e237-e243

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Kristien Cloots (K)

Institute of Tropical Medicine, Antwerp, Belgium. Electronic address: kcloots@itg.be.

Surendra Uranw (S)

B P Koirala Institute of Health Sciences, Dharan, Nepal.

Bart Ostyn (B)

Institute of Tropical Medicine, Antwerp, Belgium.

Narayan Raj Bhattarai (NR)

B P Koirala Institute of Health Sciences, Dharan, Nepal.

Epke Le Rutte (E)

Institute of Tropical Medicine, Antwerp, Belgium; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.

Basudha Khanal (B)

B P Koirala Institute of Health Sciences, Dharan, Nepal.

Albert Picado (A)

Foundation for Innovative New Diagnostics, Geneva, Switzerland.

François Chappuis (F)

Geneva University Hospitals, Geneva, Switzerland; University of Geneva, Geneva, Switzerland.

Epco Hasker (E)

Institute of Tropical Medicine, Antwerp, Belgium.

Prahlad Karki (P)

B P Koirala Institute of Health Sciences, Dharan, Nepal.

Suman Rijal (S)

Drugs for Neglected Diseases Initiative, Delhi, India.

Marleen Boelaert (M)

Institute of Tropical Medicine, Antwerp, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH